George Tachas on Muck Rack

George Tachas

As seen in: Science Magazine, CGTLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with George

Contact George, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mdx mice dosed with antisense to CD49d and dystrophin exon skip morpholino; reduced force loss and affected gene expression pathways support ATL1102 combination therapy in DMD patients

|
By Leonit Kiriaev, Chrystal F Tiong, Trevor Wilson, George Tachas
| biorxiv.org
Abstract Background: VLA-4 is a disease progression biomarker in patients with Duchenne Muscular Dystrophy (DMD) including those treated with corticosteroids. ATL1102 an antisense oligonucleotide (ASO) inhibitor of human CD49d chain of adhesion molecule VLA-4 shows promising phase-2 results in non-ambulant DMD stabilizing upper limb function (PUL2.0), grip strength, and MRI muscle fat fraction, compared to worsening with corticosteroids.
Open in Who Shared Issue with article?

George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles

|
By George Tachas
| CGTLive
“[We’re exploring this] as a monotherapy... because some boys don't have the exon splicing drugs available for that type of genetic condition...We're hoping [these findings] translate also into maintaining ambulation.
Open in Who Shared Issue with article?

George Tachas, PhD, on Evaluating Antisense Oligonucleotides in Non-Ambulant Boys With DMD

|
By George Tachas
| CGTLive
“The most important thing for us is, in the non-ambulant boys at the moment, which is in a phase 2b trial, that we reproduce these results of stabilizing upper limb function by the PUL 2.0 and also strength.The other things are almost like secondary beneficial effects, like maintaining muscle mass and maintaining bone, there will be additional benefits that we can hopefully bring to the treatment.” Perhceron Therapeutics’ ATL1102 modulated genetic modifiers of disease progression and fibrosis...
Open in Who Shared Issue with article?
See all 6 licensed articles (8 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified